Duncan Bridgeman
Friday 14th November 2003 |
Text too small? |
However, a policy change in accounting for foreign exchange hedges made comparisons with the same period a year ago misleading.
F&P Healthcare shares traded early yesterday at $12.05, down 20c since the interim profit announcement on Wednesday.
While net profit fell to $25.2 million, revenue growth from new products climbed 27% in US dollar terms, pushing operating revenue up 3.8% to a record $104.9 million.
The company is forecasting full year revenue of between $US120 million ($193.5 million) and $US125 million.
ABN Amro said in a research note it was reviewing its target price of $13.14 and its add recommendation on the stock. The broking house noted that the company's new obstructive sleep apnoea (OSA) flow generators would be fully established in the second half of the current financial year while its new mask products should continue to increase consumables market sha
No comments yet
Chorus considers Capital Notes offer
May 5th Morning Report
KPG - Kiwi Property announces GM Corporate Services
Mainfreight Limited - Trading Conditions Update 2 May 2025
SIML - Change to Executive Team
BAI - Divestment of education group
May 2nd Morning Report
MMH - Marsden Maritime Holdings (MMH) releases Scheme Booklet
CVT - Comvita announces change to Board of Directors
TRU - Published Saudi Arabia Study Confirms TruScreen's Results